BIOMAT Database Logo BIOMAT Database Logo

Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia. 1992

K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
August 1988, Cancer,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.
December 1989, Bone marrow transplantation,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.
August 1987, Klinische Wochenschrift,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
Treatment of refractory acute leukaemia with high dose cytosine arabinoside.
July 1982, British journal of haematology,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
January 1990, Cancer,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
August 1988, Cancer,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia.
March 1997, Blood reviews,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia.
June 1987, Seminars in oncology,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia.
February 1987, Onkologie,
K Nachbaur, and O Dietze, and M Herold, and J Thaler, and H Braunsteiner, and W Vogel
Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemia.
February 1986, Scandinavian journal of haematology,
Copied contents to your clipboard!